Below is a list of funding opportunities that may be of interest to the Ontario cancer research community.
If you wish to list a funding opportunity here, contact firstname.lastname@example.org.
Cancer Pathology Translational Research Grants
Ontario Molecular Pathology Research Network’s (OMPRN) vision is to create a province-wide network of pathologists collaborating to carry out high-quality cancer research with a clear potential for clinical utility. The OMPRN Steering Committee has developed objectives under the three broad themes of (i) Awareness & Outreach, (ii) Education, and (iii) Pathology-led Research. The Cancer Pathology Translational Research Grant (CPTRG) Streams address the latter objective by supporting projects in which the primary drivers are pathologists and the primary focus is on pathology cancer research.
Cancer Pathology Translational Research Grants will build the capacity of Ontario pathologists to undertake transdisciplinary research projects that advance the field of cancer diagnostic, prognostic or predictive testing and provide learning opportunities for pathology residents or early-career pathologists.
The Joseph and Wolf Lebovic Cancer Genomics and Immunity Fellowship Program
The Joseph and Wolf Lebovic Cancer Genomics and Immunity Fellowship Program aims to support projects that will uncover the diverse interactions between tumour and immune cells, for the development of new therapeutic strategies. The program aims to harness the power of genomic analytic tools with that of diverse animal and cellular experimental systems, through collaborative work between the Ontario Institute for Cancer Research (OICR) and the Institute for Medical Research Israel-Canada (IMRIC) scientists. IMRIC an institute of the Hebrew University.
- The program will provide support for trainees – students/postdoctoral fellows – working on joint projects between IMRIC and Ontario-based scientists addressing the interactions between cancer and immune cells;
- Two projects will be selected to receive support over a two-year period;
- Each collaborative project will support two trainees, one from each institution; and
- Each project will be funded at $80,000 CAD per year divided equally between the two institutions ($40,000 CAD per institution per year).
Use of funds
- Funding will be directed towards fellowship awards for trainees at the two institutions and travel between the institutions. Each trainee is expected to visit the partner’s lab during the grant-supported period. If applicable, remaining funds will be used for laboratory consumables; and
- Funds cannot be used towards Principal Investigator (PI) salaries, honoraria for guest lecturers or publication costs.
- OICR is making funding available to investigators based in, or formally affiliated with, an Ontario Host Institution such as a university, research institute, research hospital, or not-for-profit organization with an explicit research mandate;
- Proposals are to be submitted jointly by two PIs, one from each institute. A Digital Form has been created to facilitate the identification of potential collaborators;
- PIs may submit only one proposal per funding cycle; and
- PIs that were awarded a fellowship in the first round of the program are eligible to submit a proposal for the second round, however, the fellow cannot be the same.
Projects will be selected by a committee comprised of non-conflicted scientific experts based on:
- Scientific merit;
- Relevance to the program goals;
- Collaborative potential; and
- Achievements and abilities of the candidate trainees.
Applications must include the ‘Grant Application Form’ with the following documents appended:
- Joint project proposal (max. three pages) consisting of the following
- Research plan;
- Advantages of the collaboration;
- Trainee qualifications; and
- Planned use of funds.
- CVs for PIs, Co-applicants, and the trainee; and
- Budget and justification.
Notification of funding: early September, 2019.
Cancer Therapeutics Innovation Pipeline
The Ontario Institute for Cancer Research (OICR) established the Cancer Therapeutics Innovation Pipeline (CTIP) strategic initiative to capitalize on Ontario’s expertise in cancer biology and drug discovery. CTIP aims to support the translation of Ontario discoveries into therapeutic assets with the potential for improving the lives of cancer patients. To stimulate collaborative research with the Ontario cancer research community in the area of cancer therapeutics discovery.
This funding opportunity has now closed. Applicants will be notified of the outcome of the review in mid-June 2019.
Contact OICR’s Scientific Secretariat department: email@example.com